Industry | 制造业 | ||||||||||||||||||||||||
Company Introduction | 海尔生物医疗,成立于2005年,于2019年在上海证券交易所科创板上市(股票代码:688139),是基于物联网转型的生命科学与医疗创新数字化场景方案服务商。公司以创用户最佳体验为目标,面向医药企业、高校、科研机构等生命科学用户和医院、疾控、血站、基层公卫等医疗卫生用户,提供以智慧实验室、数字医院、智慧公共卫生、智慧用血等为代表的数字场景综合解决方案。 公司始终坚持技术领先,推动科技创新,引领产业变革。自突破生物医疗低温技术并打破国外垄断以来,公司对新技术持续研发投入,目前已形成自动化、分离、耗材、试剂等八大技术平台,相继突破高精准识别定位抓取技术、高精度变频控制技术、视觉识别技术、实验室耗材制造技术等核心技术,布局微生物培养、环境模拟、离心、高分子材料等领域,并加快自身业务布局的强化、拓展和延伸。同时公司积极融入科技强国、数字中国、健康中国等国家战略,率先融合物联网、人工智能、云计算等新兴技术,开创性地推出以智慧用血、智慧疫苗接种为代表的数字场景综合解决方案,并继续拓展至智慧实验室、院内用药自动化、公卫体检等场景,引领生物医疗产业数智化变革。 公司始终秉承“让生命更美好”的愿景,产品及解决方案已应用于全球140余个国家和地区。在国内市场,覆盖上万家医院、生物科技企业、高校科研机构、疾控、血浆站、检测机构等终端用户,包括中国人民解放军总医院(301医院)、上海瑞金医院、药明康德、上海复旦大学、中国疾控中心、华兰生物、恒瑞医药、复星医药等众多知名机构;在国际市场,网络布局不断完善,当地化布局加强,并与世界卫生组织(WHO)、联合国儿童基金会(UNICEF)等40余个国际组织保持长期持续的合作关系。 | ||||||||||||||||||||||||
Main Business | 生命科学和医疗创新数字场景解决方案 | ||||||||||||||||||||||||
Legal Representative | 刘占杰 | ||||||||||||||||||||||||
Top Executives |
|
||||||||||||||||||||||||
Top 5 Shareholder |
|
||||||||||||||||||||||||
Company Secretary | 黄艳莉 | ||||||||||||||||||||||||
Solicitors | 北京市金杜律师事务所 | ||||||||||||||||||||||||
Auditors | 安永华明会计师事务所(特殊普通合伙) | ||||||||||||||||||||||||
Tel No | 0532-88935566 | ||||||||||||||||||||||||
Fax No | 0532-88936010 | ||||||||||||||||||||||||
Website | www.haierbiomedical.com | ||||||||||||||||||||||||
haierbiomedical@haierbiomedical.com | |||||||||||||||||||||||||
Company Address |
|
||||||||||||||||||||||||
Listing Date | 25/10/2019 | ||||||||||||||||||||||||
Shares Capital |
|
||||||||||||||||||||||||
EPS(RMB)* | ¥ 1.280 | ||||||||||||||||||||||||
DPS(RMB)* | ¥ 0.515 | ||||||||||||||||||||||||
NBV Per Share(RMB)* | ¥ 13.306 | ||||||||||||||||||||||||
Market Capitalization(RMB) | 10.432B |
Only Chinese content is avaliable | |
N
/
N
: Eligible Stock for SH-HK Northbound trade (For all investors/ For institutional professional investors only)
N
: Eligible Stock for SH-HK Ex-Northbound trade (sell only)
|
|
N
/
N
: Eligible Stock for SZ-HK Northbound trade (For all investors/ For institutional professional investors only)
N
: Eligible Stock for SZ-HK Ex-Northbound trade (sell only)
|
|
* | Unadjusted Data |
Information provided by: etnet | ||
Terms and Conditions |
Risk Disclosure: |
The prices of securities may fluctuate, sometimes dramatically. The price of a security may move up or down, and may become valueless. It is as likely that losses will be incurred rather than profit made as a result of buying and selling securities. The information is for reference only, it does not constitute any offer, solicitation, recommendation, comment or any guarantee to the purchase or sale of any investment product or service. Customers should not make any investment decisions based on this information alone. |
Disclaimer: |
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources, Nanyang Commercial Bank Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information. |